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Summary The NETT study assessed the benefits of lung volume reduction surgery
(LVRS) versus medical treatment. However, data is available only on the early
outcome of LVRS (24 months). We evaluate the factors affecting the outcome at one-
year and up to 6 years after LVRS.
Thirty-seven patients underwent LVRS. Thirty-five patients, who survived the
operation for at least one-year, were followed up to 6 years. Patients’ laboratory,
clinical and scintigraphic data before surgery were reviewed retrospectively, andee front matter & 2005
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Successful LVRS with improvement of FEV1X30% at one-year was observed in 13 of
35 patients. Five of these patients had initial FEV1 values ofo20% of the predicted.
The group of patients with improvement was younger as compared to the 22 patients
without improvement (Po0:005). The younger age group used less supplemental
oxygen and had a PDiff of423%. Combinations of age under 60 years and PDiff423%
were a favorable factor (Po0:002) for successful LVRS. Thirty-four patients were
followed up to 6 years. Fifteen of the 34 patients (44.1%) remained well. Use ofElsevier Ltd. All rights reserved.
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R. Hardoff et al.1042supplemental oxygen before surgery, and FEV1 improvement of X30% at one-year
after surgery were good prognostic factors.
We concluded that the long-term success of LVRS is affected by non-dependence
on oxygen supplementation before surgery, and the one-year post-surgical
improvement of FEV1 (X30%). Based on our findings, the subgroup of patients
below 60 years old with severe disease (FEV1o20%) and heterogeneous upper lobe
emphysema (Pdiff423%) has improved outcome.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Emphysema is a chronic progressive pulmonary
disease associated with smoking and characterized
by hyperinflation of the pulmonary alveoli and
impairment of the expiratory outflow.1 Lung volume
reduction surgery (LVRS) has been offered in recent
years as a promising surgical option for severe
emphysema.2,3 The procedure was described by
Brantigan et al.4 in 1959, and includes non-anatomi-
cal wedge resection directed, if possible, to the most
affected emphysematous lung regions in order to
reduce the pulmonary volume by 20–30%. The
reduction of the emphysematous lung to a near
normal size decreases the tension on the respiratory
muscles, allowing them better contraction.5,6 Remov-
ing areas of non-functional lung causes improvement
in the elastic recoil and in diaphragmatic function.7
Lung imaging using chest X-ray, high-resolution
CT and lung perfusion scintigraphy, has been used
prior to LVRS for assessment of the areas for
reduction, as well as for prediction of the short-
term success of the procedure.8–11 Recently, the
National Emphysema Treatment Trial (NETT)
study12 assessed the benefits of LVRS versus medical
treatment. However, data is available only on the
early outcome (24 months) of LVRS.
The objective of this study was to evaluate the
short (one-year) and the long-term (up to 6 years)
predictive value of the preoperative clinical and
pulmonary function tests (PFTs) as well as the
quantitative analysis of preoperative perfusion lung
scintigraphy in patients undergoing LVRS.Material and methods
Patients
Thirty-seven patients with emphysema underwent
bilateral upper lobe LVRS. The inclusion criterion
for surgery was New York Heart Association class
3,13 which was used to describe the extent of
dyspnea and fatigue. Patients with TLC4110,RV4150, DLCOo65 and 6min walking distance of
4100m were included. Exclusion criteria were:
PCO2450, pulmonary hypertension450mm Hg,
6min walk of less than 100m, and steroid use of
more than 20mg prednison, We did not exclude
patients with FEV1 valueso20%. High-resolution CT
was performed in all patients as a part of the
diagnostic process, but homogenous pattern of
emphysema was not an exclusion criterion.
Bilateral surgery was performed using a mid-
sternotomy approach.
Two patients died postoperatively due to intract-
able air leak and infection, and therefore, were
excluded from further analysis.
Preoperative and postoperative information was
collected from patients’ charts. Patients used
continuous (24 h) supplemental rest oxygen when
their oxygen saturation was less than 90% or PO2
less than 55mmHg.
The PFTs included spirometry, lung volume,
maximal voluntary ventilation (MVV), 6min walk
and diffusion capacity (DLCO). PFT measurements
were corrected for body temperature and pressure
saturated (BTPS). Testing was performed with the
Medical Graphics Pulmonary Function System
(1070-series 2, St. Paul, MN, USA). Lung volumes
were obtained by body plethysmography (model
1085, Medical Graphics, St. Paul, MN, USA). MVV
was assessed by asking the patient to breath
simultaneously as fast and as deep as possible for
12 s and the result was multiplied by 5. DLCO was
measured by single breath technique with a gas
mixture containing air, 10% helium, and 0.3%
carbon monoxide. Each DLCO measurement was
adjusted to standard temperature and pressure.
The predicted value of the parameters was
obtained from the regression equations of the
European Community for Coal and Steel.14 Informa-
tion concerning 6min walking distance, use of
supplemental oxygen, use of steroids and the New
York Heart Association class,13 was also recorded.
Patients’ follow-up consisted of laboratory and
clinical data collected at one-year, and at the end
of data collection on December 2003, resulting in a
follow-up period of up to 6 years.
ARTICLE IN PRESS
Figure 1 Perfusion difference (PDiff) was defined as the
difference of percent perfusion between both lower
thirds and upper thirds of the lung fields. Patients with
PDiff423% were considered to have inhomogeneous
pattern of their lung parenchyma, while PDiffp23% was
considered to be consistent with homogenous pattern.
Outcome of Lung Volume Reduction surgery 1043Lung scintigraphy
Perfusion lung scintigraphy was performed prior to
surgery. Patients were injected intravenously in the
supine position with 74–111MBq (2.0–3.0mCi) of
technetium 99m macroaggregated albumin (DuPont
Pharma Ltd) containing 200,000–400,000 particles.
Four views (anterior, posterior, left and right
anterior oblique) were acquired for 600,000 counts.
Image analysis
Image analysis was performed on the posterior
view. The posterior view frame was rotated 901
clockwise, thus the left lung was on top of the right
lung (lying on the side), with the base of the lungs
oriented to the left of the rotated frame and the
apices to its right. Rectangular regions of interest
(ROI) were drawn on the left and right lungs,
respectively. Count distribution histograms were
derived from each ROI. The area under the curve
represented the total counts for each lung. The
inter-observer variation for the total lung counts
was estimated to be 3%, using multiple measure-
ments. The areas under the curve in the proximal
and distal halves on the X-axis of the curve,
representing the counts of the lower and upper
half of the lung, respectively, were recorded. An
additional analysis was performed for the lower,
middle and distal thirds of the X-axis representing
the counts of the lower, middle and upper thirds of
the lungs, respectively. The upper two-thirds count
value was also calculated. The distribution of lung
perfusion of the various lung regions was expressed
as the percentage of counts of that region from the
total lung counts. An additional parameter of
perfusion difference (PDiff) was defined as the
difference of percent perfusion between the lower
and upper third of the lung fields and it was used as
parameter of homogeneity of the distribution of
perfusion within the lung fields. We did not include
the middle lung field in the calculations as this area
has the most signal cross talk from the upper and
lower thirds and is poorly defined. Patients with
PDiff larger than the median value of the whole
patient population were considered to have in-
homogeneous pattern of their lung parenchyma,
while PDiff less or equal to the median value were
considered to be consistent with homogenous
pattern (Fig. 1).
Follow-up
The outcome of surgery at one-year was evaluated
using the percent change in FEV1 compared tobaseline values before LVRS, 6min walking dis-
tance, use of oxygen and steroids as well NYHA
class. A surgical mechanical success at one-year
was judged as an improvement in FEV1 of X30%
following surgery. Therefore, patients were divided
into two groups: patients with FEV1 improvement of
X30% and patients with FEV1 improvement of
o30% after surgery. Since an improvement of
FEV1X30% is a strict criterion for successful
surgery, it was expected that some patients who
did not achieve this mechanical improvement and
were included in the second group would benefit
from LVRS, resulting in improvement of their
clinical status.
The study end points of the long-term follow-up
consisted of two end points: (1) death or lung
transplantation and (2) deterioration of NYHA class
to X3.13Statistical analysis
Paired Student’s t-tests were performed to deter-
mine the significance of the pre-surgical clinical,
laboratory and scintigraphic parameters in the
improvement in clinical outcome and PFTs. The
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Student’s t-test between the two subgroups
(FEV1X30%, or FEV1o30%) after LVRS. Kaplan–
Meier curves were used for survival analysis.
A P value of less than 0.05 was considered to be
statistically significant.Results
Preoperative data
After the exclusion of the two patients who died
postoperatively, the patient population consisted
of 25 males and 10 females (age 5977, range
43–74). Patients’ clinical and PFTs before LVRS are
summarized in Table 1. Twenty-two patients
(62.9%) were under 60 years old. All patients
were classified as New York Heart Association 3,
namely unable to perform less than ordinary
activity.12
Twenty-eight of the 35 (80%) patients received
prednisone therapy (10 patients—10mg, 6 pa-
tients—15mg, 12 patients—20mg). Twenty of the
35 patients (57%) used supplemental oxygen on a
regular basis before LVRS.Table 1 Patients’ clinical and pulmonary function
tests (% predicted) prior to LVRS (n ¼ 35).
Range Mean7SD
Clinical data
Age 43–74 58.677.1
6min walking (m) 100.0–500.0 300.67123.0
Prednison (mg) 0.0–20.0 12.377.4
Pulmonary function tests
FEV1 13.0–50.0 27.879.1
FVC 30.0–90.0 57.0714.5
TLC 110–188.0 136.5717.3
RV 151.0–483.0 271.6758.8
RV/TLC 60.0–86.0 73.075.9
DLCO 17.0–65.0 44.2713.4
Lung perfusion scintigraphy
Lower thirda 20.0–60.0 39.179.7
Middle third 33.0–56.0 44.675.5
Upper third 7.0–32.0 16.376.5
Upper 2/3 40.0–80.0 60.979.7
Upper half 19.0–63.0 36.3711.07
Lower half 36.0–81.0 63.0711.7
Pdiffy 10.0–53.0 23.0715.7
aAll values were expressed in % of total lung counts.
Lower third denotes lower third of the right and left lung.
yPDiff is the difference of percent perfusion between
both lower thirds and upper thirds of the lung fields.The regional relative lung perfusion values of the
patient population prior to LVRS, are also described
in Table 1. These parameters are variables and
their range is large.Postoperative follow-up at one-year
Clinical outcome
One-year after surgery, 13 (36%) of the 35 patients,
had a significant improvement of FEV1 of X30%
(65.4725.6%, range 41–119%) and were considered
as mechanical success of LVRS, and 22 patients had
a mild improvement of FEV1 ofo30% [(mean
5.3718.2%, range (50)–29%), Po0:001]. Within
the mild improvement group, 10 patients had some
improvement of FEV1 (though less than 30%), of
6min walking distance, as well as a decrease in O2
and steroid use (Table 2).
Table 3 describes the prognostic values of several
demographic (age, sex), clinical (use of supple-
mental oxygen) and PDiff as prognosticators for
mechanical success of LVRS. No sex difference was
detected between patients with successful and
unsuccessful LVRS. The PFTs before surgery were
not different in the 13 patients with mechanical
successful LVRS as compared to the 22 patients with
no successful LVRS.
Patients who did not use oxygen before surgery
were more likely to benefit from LVRS (8 of 15
patients, 53%), compared to patients who were
oxygen-dependent [(5 of 20 patients, 25%), one
tailed P ¼ 0:043].
Younger age was also a favorable prognostic
indicator for successful LVRS. Patients under the
age of 60 years had a favorable outcome in 54.5%
(12 of 22 patients), while patients who were 60
years or older had a favorable outcome in only 7.7%
(1 of 13 patients, P ¼ 0:005). Patients’ mean age
with favorable outcome (FEV1X30%) was 54.475.5
years (range 43.8–60.0), while patients in whom
LVRS caused an in improvement of FEV1o30% had
mean age of 61.176.9 (range 47–74), (Po0:005).
Five of the eight patients whose FEV1 values before
surgery were o20%, had a mechanical success of
LVRS. Six of these patients used oxygen and
steroids.Scintigraphy
Uptake in the various lung fields (upper, middle and
lower thirds, upper and lower half and upper two-
thirds) was not predictive of LVRS outcome. The
median PDiff of the group was 23% (mean
22.9715.6), and as mentioned was used as para-
meter of homogeneity of the distribution of
perfusion within the lung fields. Patients with PDiff
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Table 2 Patients clinical and pulmonary function tests (% predicted) data one-year after LVRS (n ¼ 35).
FEV1X30%
 ðn ¼ 13Þ FEV1o30% ðn ¼ 22Þ P value
FEV1 44.8720.0 29.3710.5 0.02
FEV1% improvement 65.4725.6 5.3718.2 0.001
FVC 86.3722.3 67.4720.8 0.017
TLC 123.7712.8 122.8722.1 n.s.
RV 208.3756.7 214.7742.8 n.s.
RV/TLC 58.5712.8 66.9710.4 0.046
DLCO 58.2721.1 49.5718.7 n.s.
6min walking (m) 488.7793.6 393.7791.1 0.06
Patients are divided according to their FEV1 one-year after LVRS.
Table 3 Prognostic value of different clinical and scintigraphic parameters.
FEV1 improvement X30%
ðn ¼ 13Þ
FEV1 improvement o30%
ðn ¼ 22Þ
P value
Sex
Male 10 15
n.s.
Female 3 7
Age
o60 12 10
0.01
X60 1 12
O2 use
No 8 7
0.043
Yes 5 15
*Pdiff
423% 9 7
0.04
p23% 4 15
PDiff423% 8 2
Ageo60 0.002
All other patients 5 20
PDiff is the difference of percent perfusion between the lower thirds and upper thirds of both lung fields.
Outcome of Lung Volume Reduction surgery 1045423% were considered to have inhomogeneous
pattern of their lung parenchyma, while PDiff
p23% was considered to be consistent with homo-
genous pattern (Fig. 1).
Nine of 16 patients (56.3%) with PDiff423%
improved their FEV1X30%. Only 4 of 19 patients
(21.1%) with PDiffp23% had such an improvement
(P ¼ 0:04). Younger patients (under 60 years of age)
with PDiff423% benefited from surgery more than
older patients with PDiff423%, or from younger
patients with PDiffp23%. Of the 22 younger
patients, 10 patients had a PDiff of 423%. Eight
of these 10 patients (80%) improved their
FEV1X30%. Only four patients of the remaining12patients (33%) under the age of 60 years and
PDiffp23%, improved their FEV1X30% (P ¼ 0:04).
Thus, inhomogeneous lung parenchyma was a
moderate predictor of success of LVRS in patients
under 60 years of age.
Long-term postoperative follow-up
Of the 35 patients, one patient with improvement
in FEV1X30% at one-year moved abroad and was
lost for follow-up. Therefore, 34 patients were
followed up to 6 years (mean 54.3716.6 months,
range14–72 months).
During the follow-up period, six patients under-
went lung transplantation, and five patients died
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Figure 2 Survival function of patients with or without
pre-surgical use of oxygen supplementation (no O2
use—patients who did not use supplemental oxygen).
Prediction of death and lung transplantation (as end
point events (A, Po0.047)). Deterioration to NYHA class
of X3 (B, Po0.005) in the long-term follow-up of LVRS.
R. Hardoff et al.1046without undergoing lung transplantation. Of the
remaining 23 patients, four patients remained in
NYHA class of X3 after LVRS and additional four
patients deteriorated to NYHA class of X3, at the
time of the termination of the study. Fifteen of the
34 patients (44.1%) remained well.
The long-term follow-up of the group of the 12
patients judged to have successful mechanical
outcome (improvement of FEV1X30%,), showed
that one patient died at 16 months after LVRS,
and two patients underwent lung transplantation at
54 and 62 months, respectively. These two patients
had a pre-surgical FEV1values of o20%.
The remaining nine patients were well, and their
NYHA class was 2.5 or less. This group included four
patients with pre-surgical FEV1 values of o20%.
Three of these four patients had a pre-surgical Pdiff
of 423%. Five patients who had pre-surgical FEV1
values of440%, were well at the end of the follow-
up period.
Of the 22 patients in whom FEV1 improved
byo30% after LVRS, four patients died at the end
of the study, and four underwent lung transplanta-
tion. Eight patients had a NYHA class of X3 at the
end of the study (four did not improve following
LVRS and four deteriorated). Five patients main-
tained their clinical improvement after LVRS
throughout the follow-up and one patient had
succeeded in improving his NYHA class from 3.0 to
2.0, in spite of no improvement in FEV1, due to
intense exercise program.
No difference in follow-up time interval was
found between patients with and without mechan-
ical success of LVRS (56714.8 vs. 47.5716.8
months, respectively). At the end of follow-up
period, 9 of the 12 (75%) patients who had a
mechanical success remained clinically well, while
only 6 of 22 (27%) patients in the second group
(FEV1 improvement of less than 30%), benefited
from LVRS (Po0:01).
The use of supplementary oxygen before surgery
was the only pre-surgical predictor for the outcome
of the major events (Fig. 2A, Po0:047) and even a
stronger predictor for deterioration to NYHA class
of X3, (Fig. 2B, Po0:005).
No difference in major event (death/lung trans-
plantation) and in deteriorating to NYHA class of
X3 could be predicted by age, sex, pre-surgical
prednisone use, 6min walking distance as well as
PDiff of 423% (Po0:08). The combination of age
under 60 years and PDiff 423%, was not a
significant predictor of a long-term favorable out-
come of LVRS.
The major events: death and lung transplanta-
tion were not significantly affected by the im-
provement in FEV1. The clinical deterioration toNYHA classX3, however, was significantly inversely
correlated with FEV1 improvement (Fig. 3,
Po0:023).
Therefore, patients who survived at least a year
after LVRS and had an improvement of more than
30% in their FEV1, had a long-term clinical benefit
from the procedure.Discussion
Current criteria for patient selection for LVRS are
based on the NETT study that found survival
advantage for patients with both predominantly
upper-lobe emphysema and low base-line exercise
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Figure 3 Survival function of patients with and without
improvement of FEV1X30% at one-year after LVRS. The
clinical deterioration to NYHA class of X3 was inversely
associated with the improvement of FEV1X30%
(Po0:023).
Outcome of Lung Volume Reduction surgery 1047capacity.12 The rational for the surgery in this
subgroup of patients is that the severe emphyse-
matous tissue is compressing the normal lung
tissue. Surgical removal of the compressing areas
may lead to expansion of the remaining lung and
improve its capacity for perfusion and ventilation.
On the other end of the spectrum are patients in
whom the entire lung fields are involved with
homogenous emphysema and had high base-line
exercise capacity, are considered to be the poorest
candidates. Many of the patients however, do not
belong to either category and they are in between
these two extreme conditions.15
Lung imaging, both radiological and scintigraphic,
has been recognized as an important tool in the pre-
surgical evaluation of candidates for LVRS.8–11,15–22
It can assist in determining which areas are more
affected by the emphysematous process, have
impaired perfusion and ventilation and therefore
can be safely resected. Maki et al.8 using visual
scores in different lung zones, suggested that chest
radiographs alone are satisfactory in achieving this
goal. Differences within zones,8,9 or the extent of
emphysema among adjacent zones,9 were also
compared. Radiological assessment with various
techniques of analysis has recently become a tool
in the assessment of patients prior to LVRS.16,17,19–21
High-resolution CT (HRCT), spiral CT and perfusion
lung scintigraphy,9,11,16–21 applying subjective, scor-
ing, semi-quantitative and quantitative methods,
have also been used.Our patients were not excluded, however, on the
basis of diffuse disease on HRCT. Semi-quantitative
analysis of lung scintigraphy is fast, easy to perform
on any system, and is highly reproducible. The PDiff
is readily calculated from the lung histogram and
provides an objective parameter for the assessment
of lung heterogeneity. A recent study18 has used
perfusion scintigraphy for the evaluation of pa-
tients prior to bilateral upper lobe LVRS. The
authors found that patients with reduced perfusion
to their upper lobes increased their FEV1 at a short-
term follow-up of 3–6 months, compared to those
with higher apical perfusion.
In our study, one-year after LVRS, patients with
PDiff423% benefited from surgery, while most
patients with PDiffp23% did not. Benefit was also
observed in patients with FEV1o20%, and
PDiff423%. A combination of younger age (o60
years) and PDiff 423% proved to be even more
favorable. The lack of use of supplementary oxygen
was also a favorable factor for successful LVRS.
We also assessed whether the improvement
observed after a year is only temporary, or it is
maintained for an extended period of time affect-
ing both survival and the long-term clinical status
of these patients. Patients who did not need oxygen
before LVRS had not only a better mechanical
success of the procedure, but also a better long-
term survival and improved clinical status.
Patients who survived one-year of surgery and
had an improvement of their FEV1 at least 30%, had
better long-term clinical outcome. Our inclusion
criteria in 1996, when the LVRS program started,
included all patients with NYHA class of 3. Patients
with homogenous emphysema, low FEV1 values, or
patients treated with steroids and oxygen were not
excluded, since the concept was that these
patients might also benefit from this procedure.
As we followed up these patients and the literature
provided more information, others and we have
learned that the outcome of LVRS is better in
younger patients who are not oxygen dependent
and their FEV1 is above 20%. In spite of this
statement, a subgroup of eight patients with a
pre-surgical FEV1 value ofo20%, (six of whom used
supplemental oxygen and steroids) had LVRS. Five
of these patients had a successful outcome at one-
year and four of the eight patients remained well at
the end of the follow-up. Three of these patients
showed an inhomogeneous pattern of perfusion
distribution with Pdiff 423%. According to the
standard of care today, these patients would have
been considered as unfavorable candidates for
LVRS.
Naunheim et al.22 who used bilateral thoraco-
scopic LVRS (which is less invasive than an open
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term survival. The mortality rate in their series
approached 30% at 3 years, raising the question
whether LVRS offers survival advantage to these
patients. Gelb et al.23 looked at the outcome of
LVRS 4 years after surgery in 26 patients with severe
heterogeneous emphysema. At 4 years, mortality
was 46%. Surgery provided clinical and physiologic
improvement compared to baseline in 9 of the 26
patients (35%). This group had a greater pre-
surgical VC and FVC compared to 10 patients who
were considered responders (at a short-term
follow-up), who died less than 4 years after LVRS.
Our data are similar to those described by Gelb et
al.23 Eleven of the 34 (32%) patients, died or had
lung transplantation and additional eight deterio-
rated clinically. Thus, a total of 19 patients (55.8%)
did not sustain a long-term improvement after
LVRS, There were 15 (44.1%) patients who improved
clinically following LVRS, 12 of whom (35.2%) had
an improvement in FEV1X30% as compared to the
baseline values.
The NETT study assessed the 2-year outcome of
LVRS versus medical treatment.12 Their database
consisted of 1218 patients recruited between
January 1998 and June 2001 and the group will
report the 2-year outcome of this cohort in the near
future. Patients’ imaging consisted of analysis of
the CT images providing a score of homogeneity. A
subgroup of 139 severely ill patients from the above
cohort, who all had FEV1 values of no more than
20% and either homogeneous lung pattern or DLCO
o20% of the predicted, were randomized. It was
found that these patients did not benefit from
LVRS. Recently, a full report of the whole cohort has
been published.24 They found that except for these
139 patients, surgery exercise capacity was better
in the surgery group, while mortality was not
different as compared to the medical treatment
group. A subgroup of patient who underwent
bilateral upper lobe LVRS, had lower mortality then
the medical treated group. Furthermore, 25 of 84
patients with low exercise capacity improved their
exercise capacity at 24 months after LVRS. They
explained the better survival in this subgroup of
patients, due to the progressive functional limita-
tion of these patients leading to high mortality
when they are treated medically. There is no
information yet what is the long-term benefit of
this procedure. We provide this information in a
limited number of patients. Since our patients
underwent bilateral upper lobe LVRS, our relatively
good results, even in patients with FEV1 values
ofo20%, are in concordance with the results of the
NETT not only at 24 months, but 60 months as well.
It seems that a 2-year follow-up of the wholecohort of NETTwill have to be extended in order to
provide sufficient data concerning the long-term
effect of the procedure, especially in the group
with the ‘‘anatomically favorable disease’’.25
In conclusion, in our series, although small, LVRS
was found to be beneficial in 44.1% of the patients
who underwent bilateral upper lobe resection.
Patients’ selection should be based on both clinical
parameters such as age and use of supplemental
oxygen, and on imaging parameters (PDiff423), in
order to define the best group of patients who will
benefit from the operation. FEV1o20% in itself
should not be considered as a contraindication for
LVRS. The future results of the long-term follow-up
of the NETTwill contribute to better definition of the
prognostic factors for successful LVRS and provide
guidelines for choosing patients for this procedure.References
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